Related Experiment Video

Updated: Mar 13, 2026

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy
08:40

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

18.8K

Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity

Qiong Liu1, Wen Wen2, Liang Tang2

  • 1International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Institute, Second Military Medical University, Shanghai, P.R. China; Naval Medical Research Institute, Shanghai, China.

Oncoimmunology
|October 21, 2016
PubMed

Insights

Signal regulatory protein alpha (SIRPα) inhibits dendritic cell (DC) survival and activation in liver cancer, promoting immune tolerance. Inhibiting SIRPα enhances DC function, boosting anti-tumor immunity and potentially improving cancer vaccines.

Area of Science:

  • Immunology
  • Oncology
  • Cell Biology

Background:

  • Dendritic cells (DCs) are crucial for anti-tumor immunity but can become tolerogenic.
  • Signal regulatory protein alpha (SIRPα) is implicated in immune regulation.

Purpose of the Study:

  • To investigate the role of SIRPα in dendritic cell function within the tumor microenvironment.
  • To determine if SIRPα inhibition can enhance anti-tumor immune responses.

Main Methods:

  • Analysis of SIRPα expression in dendritic cells from human liver cancer tumors.
  • Silencing of SIRPα in dendritic cells.
  • Assessment of dendritic cell survival, activation markers (IL-12, costimulatory molecules), and cytotoxic T lymphocyte responses.
  • Investigation of SIRPα's molecular mechanism involving PI3K.

Main Results:

  • Elevated SIRPα expression in tumor-infiltrating DCs correlates with immune tolerance.
  • Silencing SIRPα increased dendritic cell longevity and spontaneous IL-12 and costimulatory molecule production.
  • SIRPα inhibition led to enhanced cytotoxic T lymphocyte responses and tumor eradication.
  • SIRPα interacts with the p85 subunit of PI3K.

Conclusions:

  • SIRPα acts as a critical inhibitor of dendritic cell lifespan and activity.
  • Targeting SIRPα may enhance the efficacy of dendritic cell-based cancer vaccines.
Keywords:
AktSIRPαantitumor immunitydendritic cells

More Related Videos

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes11:48

Isolation Protocol of Mouse Monocyte-derived Dendritic Cells and Their Subsequent In Vitro Activation with Tumor Immune Complexes

Published on: May 31, 2018

12.2K
Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface13:36

Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface

Published on: October 20, 2023

4.3K

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K